X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9958) 9958
Book Chapter (98) 98
Dissertation (26) 26
Book / eBook (3) 3
Conference Proceeding (3) 3
Magazine Article (3) 3
Newspaper Article (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nonalcoholic steatohepatitis (7038) 7038
humans (5113) 5113
male (3838) 3838
gastroenterology & hepatology (3062) 3062
female (2785) 2785
animals (2721) 2721
nonalcoholic fatty liver disease (2719) 2719
liver (2606) 2606
fatty liver (2591) 2591
insulin-resistance (2436) 2436
liver diseases (2340) 2340
obesity (2229) 2229
middle aged (2025) 2025
metabolic syndrome (1907) 1907
fibrosis (1806) 1806
fatty liver-disease (1790) 1790
adult (1778) 1778
insulin resistance (1778) 1778
mice (1707) 1707
disease (1673) 1673
steatohepatitis (1642) 1642
liver - pathology (1589) 1589
steatosis (1575) 1575
risk factors (1500) 1500
hepatic steatosis (1484) 1484
liver - metabolism (1470) 1470
inflammation (1378) 1378
oxidative stress (1336) 1336
non-alcoholic fatty liver disease (1322) 1322
nonalcoholic fatty liver (1254) 1254
prevalence (1155) 1155
fatty liver - pathology (1090) 1090
metabolism (993) 993
aged (973) 973
analysis (898) 898
biochemistry & molecular biology (891) 891
cirrhosis (870) 870
fatty liver - metabolism (869) 869
diet (856) 856
diabetes (831) 831
endocrinology & metabolism (815) 815
hepatocellular-carcinoma (806) 806
rodents (795) 795
mice, inbred c57bl (788) 788
nafld (786) 786
rats (776) 776
biopsy (775) 775
gastroenterology and hepatology (772) 772
lipids (764) 764
body mass index (711) 711
expression (694) 694
disease models, animal (691) 691
hepatology (691) 691
health aspects (686) 686
fatty acids (683) 683
diagnosis (671) 671
pharmacology & pharmacy (668) 668
nutrition & dietetics (665) 665
research (665) 665
liver cirrhosis (663) 663
non-alcoholic fatty liver disease - pathology (652) 652
fatty liver - etiology (642) 642
risk-factors (637) 637
natural-history (630) 630
insulin (629) 629
physiological aspects (623) 623
liver - drug effects (619) 619
pathogenesis (619) 619
medicine & public health (610) 610
digestive system diseases (600) 600
gene expression (595) 595
medicine (594) 594
hepatitis (593) 593
non-alcoholic fatty liver disease - metabolism (590) 590
nutritional and metabolic diseases (588) 588
cholesterol (570) 570
nash (562) 562
association (561) 561
lipid metabolism (555) 555
hepatocellular carcinoma (547) 547
risk (545) 545
glucose (543) 543
care and treatment (542) 542
medicine, research & experimental (532) 532
apoptosis (531) 531
disease progression (521) 521
surgery (513) 513
triglycerides (506) 506
abridged index medicus (505) 505
alanine transaminase - blood (505) 505
gastroenterology (503) 503
research article (502) 502
adipose-tissue (495) 495
obesity - complications (495) 495
review (493) 493
gene-expression (486) 486
activation (485) 485
fatty liver - complications (485) 485
liver-disease (484) 484
adolescent (482) 482
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9792) 9792
Japanese (78) 78
Korean (72) 72
French (53) 53
German (42) 42
Spanish (34) 34
Russian (27) 27
Portuguese (16) 16
Chinese (13) 13
Polish (11) 11
Hungarian (4) 4
Italian (3) 3
Turkish (2) 2
Czech (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 4, p. e62885
Journal Article
Journal of Clinical Gastroenterology, ISSN 0192-0790, 03/2006, Volume 40 Suppl 1, Issue 1, pp. S17 - S29
Journal Article
Journal Article
The American journal of clinical nutrition, ISSN 1938-3207, 2004, Volume 79, Issue 3, pp. 502 - 509
Journal Article
Liver international, ISSN 1478-3223, 2017, Volume 37, Issue S1, pp. 97 - 103
...‐alcoholic steatohepatitis, NASH). NASH, the more aggressive form of NAFLD, may progress to cirrhosis and hepatocellular carcinoma... 
non‐alcoholic steatohepatitis (NASH) | peroxisome proliferator‐activator receptor (PPAR) agonists | farnesoid X receptor (FXR) | non‐alcoholic fatty liver disease (NAFLD) | ROS (reactive oxygen species) | glucagon‐like peptide (GLP‐1) agonist | non-alcoholic fatty liver disease (NAFLD) | glucagon-like peptide (GLP-1) agonist | peroxisome proliferator-activator receptor (PPAR) agonists | non-alcoholic steatohepatitis (NASH) | VITAMIN-E | ACID | RANDOMIZED-TRIALS | AMERICAN ASSOCIATION | FATTY LIVER-DISEASE | WEIGHT-LOSS | GLUCAGON-LIKE PEPTIDE-1 | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | PENTOXIFYLLINE | Hypoglycemic Agents - therapeutic use | Liver Cirrhosis - etiology | Liver - pathology | Liver Transplantation | Humans | Risk Factors | Non-alcoholic Fatty Liver Disease - therapy | Disease Progression | Randomized Controlled Trials as Topic | Liver Neoplasms - etiology | Non-alcoholic Fatty Liver Disease - complications | Thiazolidinediones - therapeutic use | Exercise | Diet | Fibrosis | Vitamin E - therapeutic use | Carcinoma, Hepatocellular - etiology | Liver diseases | Syngeneic grafts | Pathogenesis | Liver | Pioglitazone | Viruses | Hepatocellular carcinoma | Transplantation | Infections | Steatosis | Hepatitis | Cirrhosis | Fatty liver | Cell injury | Hepatocytes | Vitamin E | Hepatitis C virus | Hepatitis C | Tocopherol | Liver transplantation | Nonalcoholic fatty liver disease (NAFLD) | Farnesoid X receptor (FXR) | Glucagon-like peptide (GLP-1) agonist | Peroxisome proliferator-activator receptor (PPAR) agonists | Nonalcoholic steatohepatitis (NASH)
Journal Article